1.91  0.01 (0.53%)		05-01 14:17
Open: 1.895 High: 1.94 Volume: 252,923		Pre. Close: 1.9 Low: 1.855 Market Cap: 553(M)

Short term
Mid term
Targets	6-month :	2.55	1-year :	2.98
Resists	First :	2.19	Second :	2.55
Pivot price	1.96
Supports	First :	1.8	Second :	1.55
MAs	MA(5) :	1.86	MA(20) :	1.94
	MA(100) :	2.11	MA(250) :	2.16
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	28.7	D(3) :	20
RSI	RSI(14): 47.3
52-week	High :	7.13	Low :	0.54

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PROK ] has closed above bottom band by 35.7%. Bollinger Bands are 19.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.93 - 1.94	1.94 - 1.95
Low:	1.79 - 1.81	1.81 - 1.82
Close:	1.87 - 1.9	1.9 - 1.92

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Fri, 01 May 2026
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel - Insider Monkey

Thu, 30 Apr 2026
[SCHEDULE 13D/A] PROKIDNEY CORP. Amended Major Shareholder Report - Stock Titan

Thu, 30 Apr 2026
Control Empresarial converts 63.1M PROK (NASDAQ: PROK) Paired Interests into Class A shares - Stock Titan

Fri, 17 Apr 2026
ProKidney (NASDAQ:PROK) Stock Price Up 9% - Should You Buy? - MarketBeat

Thu, 16 Apr 2026
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Tue, 31 Mar 2026
What Makes ProKidney Corp. (PROK) So Attractive - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	142 (M)
Held by Insiders	9.367e+007 (%)
Held by Institutions	25.3 (%)
Shares Short	15,570 (K)
Shares Short P.Month	0 (K)

EPS	-1.5843e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-20 %
Return on Assets (ttm)	306.2 %
Return on Equity (ttm)	-26.6 %
Qtrly Rev. Growth	893000 %
Gross Profit (p.s.)	105.43
Sales Per Share	-23.21
EBITDA (p.s.)	480108
Qtrly Earnings Growth	-0.6 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-120 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.09
Price to Cash Flow	-0.5

Dividend	0
Forward Dividend	1.668e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.